Biocon Chief Urges Middle-Ground On IP Dispute With Other Nations
This article was originally published in PharmAsia News
Biocon Chairman and Managing Director Kiran Mazumdar-Shaw is urging a middle-ground approach by India drug makers to the continuing U.S. pressure on intellectual-property issues, but said they would not be bullied.
You may also be interested in...
Advanced Imaging Group Calls For Swifter FDA Approvals For Mobile X-Ray, CT, Ultrasound Devices For COVID-19 Crisis
The Medical Imaging & Technology Alliance (MITA) recently sent a letter to the US FDA recommending steps the agency can take to help the advanced imaging industry quickly respond to the COVID-19 outbreak.
The two-year results from the PARTNER 3 trial showed transcatheter aortic valve replacement with Edwards Lifesciences' Sapien 3 system was statistically non-inferior to surgical valve replacement in low-risk patients. The one-year results from the trial had shown TAVR was superior to surgery in low-risk patients.
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.